[go: up one dir, main page]

AR075368A1 - Inhibidores de glicosilceramida sintasa - Google Patents

Inhibidores de glicosilceramida sintasa

Info

Publication number
AR075368A1
AR075368A1 ARP100100327A ARP100100327A AR075368A1 AR 075368 A1 AR075368 A1 AR 075368A1 AR P100100327 A ARP100100327 A AR P100100327A AR P100100327 A ARP100100327 A AR P100100327A AR 075368 A1 AR075368 A1 AR 075368A1
Authority
AR
Argentina
Prior art keywords
alkyl
heteroaryl
haloalkyl
independently
ring
Prior art date
Application number
ARP100100327A
Other languages
English (en)
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AR075368A1 publication Critical patent/AR075368A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Moduladores de glucosilceramida sintasa (GCS) y métodos para hacer los compuesto. Comprende además composiciones que comprenden los compuestos, N-oxidos, y/o sales farmacéuticamente aceptables de los mismos. También comprende el uso de los compuestos y composiciones para la fabricacion de medicamentos, particularmente para tratar enfermedades en las cuales GCS es un mediador o está implicado. Reivindicacion 1: Un compuesto de la formula (1), o un estereoisomero sencillo o mezcla de estereoisomeros de los mismos, N-oxidos de los mismos, y de manera adicional opcionalmente como una sal farmacéuticamente aceptable de los mismos, caracterizado porque A es isopropilo, t-butilo, cicloalquilo C3-8, heterociclilo, arilo, o heteroarilo, en donde el cicloalquilo, heterociclilo, arilo, y heteroarilo están opcionalmente sustituidos por uno, dos o tres grupos RA, en donde cada RA es independientemente RA2, alquilo C1-4, haloalquilo C1-4, arilo, arilalquilo C1-4, o alquilo C1-4-RA2, en donde el arilo del grupo arilalquilo C1-4 está opcionalmente sustituido con uno, dos o tres grupos RA2, en donde, cada RA2 es independientemente halogeno, ciano, nitro, -ORA1, -SRA1, -N(RA1)2, -C(O)RA1, -S(O)RA1, -S(O)2RA1, -S(O)N(RA1)2, -S(O)2N(RA1)2, -C(O)ORA1, -C(O)N(RA1)2, -N(RA1)C(O)RA1, -N(RA1)C(O)ORA1, -N(RA1)C(O)N(RA1)2, -N(RA1)S(O)2RA1, -N(RA1)C(=NRA1)N(RA1)2, -P(O)(ORA1)2, o -OP(O)(ORA1)2, en donde cada RA1 es independientemente hidrogeno, alquilo C1-4, o haloalquilo C1-4, o dos RA enlazados a átomos de carbono adyacentes, tomados juntos, forman -O-(G)y-O-, en donde cada G es independientemente -CH2-, -C(H)(F)-, o -CF2-, e y es 1, 2, o 3; L es -[C(RL)2]p-L1-[C(RL)2]q-, en donde p es 1, 2, o 3; q es un entero seleccionado de 0 hasta (3-p); L1 es una union u -O-; y cada RL es independientemente hidrogeno, metilo, o halometilo; R1 es -N(R10)(R11) o una porcion de la formula (2), en donde R10 es hidrogeno o alquilo C1-4; R11 es -R13,-cicloalquilo C3-6-N(R12)2, -cicloalquilo C3-6-R13, alquilo C1-4-N(R12)2, o alquilo C1-6-R13, en donde cada R12 es independientemente hidrogeno o alquilo C1-4; y R13 es (a) un anillo heterociclilo monocíclico de 4-10 miembros, bicíclico fusionado de 4-10 miembros, bicíclico puenteado de 5-10 miembros, o bicíclico espiro de 5-10 miembros, donde el anillo heterociclilo comprende uno, dos o tres átomos de nitrogeno anular, y opcionalmente comprende un átomo de oxígeno o azufre anular, o (b) un heteroarilo monocíclico de 5 o 6 miembros o un heteroarilo bicíclico fusionado de 8-10 miembros, donde el anillo heteroarilo comprende uno, dos, o tres átomos de N anulares, y opcionalmente comprende un átomo de O o S anular, en donde el heterociclilo y heteroarilo están cada uno opcionalmente sustituidos con uno, dos, o tres, grupos R13A, en donde cada grupo R13A es independientemente halogeno, ciano, nitro, alquilo C1-4, haloalquilo C1-4, arilalquilo C1-4, -ORB1, -SRB1, -N(RB1)2, -C(O)RB1, -S(O)RB1, -S(O)2RB1, -S(O)N(RB1)2, -S(O)2N(RB1)2, -C(O)ORB1, -C(O)N(RB1)2, -N(RB1)C(O)RB1, -N(RB1)C(O)ORB1, -N(RB1)C(O)N(RB1)2, o -N(RB1)S(O)2RB1, en donde cada RB1 es independientemente hidrogeno, alquilo C1-4, haloalquilo C1-4,arilo, o arilalquilo C1-4, w es 0, 1, 2, o 3; el anillo B en la definicion de R1 es (a) un anillo heterocíclico monocíclico de 4-10 miembros, bicíclico fusionado de 4-10 miembros, bicíclico puenteado de 5-10 miembros, o bicíclico espiro de 5-10 miembros, donde el anillo heterociclilo opcionalmente comprende un átomo de oxígeno o azufre anular, y opcionalmente uno, dos, o tres átomos de nitrogeno anulares adicionales, o (b) un heteroarilo monocíclico de 5 o 6 miembros o un heteroarilo bicíclico fusionado de 8-10 miembros, donde el anillo heteroarilo opcionalmente comprende un átomo de oxígeno o azufre anular, y opcionalmente uno, dos, o tres átomos de nitrogeno anulares adicionales; R20 es -RB2, hidrogeno, alquilo C1-4, haloalquilo C1-4, cicloalquilo C3-8, arilalquilo C1-4, o alquilo C1-4-RB2, donde cada RB2 es independientemente ciano, nitro, -ORB3, -SRB3, -N(RB3)2, -C(O)RB3, -S(O)RB3, -S(O)2RB3, -S(O)N(RB3)2, -S(O)2N(RB3)2, -C(O)ORB3, -C(O)N(RB3)2, -N(RB3)C(O)RB3, -N(RB3)C(O)ORB3, -N(RB3)C(O)N(RB3)2 o -N(RB3)S(O)2RB3, en donde cada RB3 es independientemente hidrogeno, alquilo C1-4, haloalquilo C1-4, arilo, o arilalquilo C1-4; o dos RB3 tomados junto con el átomo de nitrogeno al cual ambos se enlazan forman un heterociclilo o heteroarilo monocíclico saturado o no saturado, en donde el heterociclilo y heteroarilo están cada uno opcionalmente sustituidos con uno, dos, o tres grupos los cuales son cada uno independientemente alquilo C1-3, halogeno, o haloalquilo C1-4; y cada R21 es independientemente halogeno o -R20; R2 es metilo opcionalmente sustituido con uno, dos o tres grupos halo, o ambos R2 tomados junto con el átomo de carbono al cual se enlazan forman un grupo ciclopropilo; m es 1, 2, 3, 4 o 5; y cada R3 es independientemente halogeno, ciano, nitro, alquilo C1-4, haloalquilo C1-4, cicloalquilo C3-6, -ORC1, -N(RC1)2, -C(O)RC1, -S(O)RC1, -S(O)2RC1, -S(O)N(RC1)2, -S(O)2N(RC1)2, -C(O)ORC1, -C(O)N(RC1)2, -N(RC1)C(O)RC1, -N(RC1)C(O)ORC1, -N(RC1)C(O)N(RC1)2 o -N(RC1)S(O)2RC1, en donde cada RC1 es independientemente hidrogeno, alquilo C1-4, haloalquilo C1-4, arilo, o arilalquilo C1-4, o dos R3 tomados junto con los átomos en el anillo a los cuales se enlazan forman un arilo, heteroarilo, un cicloalquilo monocíclico, o un heterociclilo, cada uno opcionalmente sustituido con uno, dos, o tres grupos los cuales son cada uno independientemente alquilo C1-3, halogeno, o haloalquilo C1-4.
ARP100100327A 2009-02-06 2010-02-05 Inhibidores de glicosilceramida sintasa AR075368A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15043409P 2009-02-06 2009-02-06
US28111609P 2009-11-13 2009-11-13
PCT/US2010/023168 WO2010091164A1 (en) 2009-02-06 2010-02-04 Inhibitors of glucosylceramide synthase

Publications (1)

Publication Number Publication Date
AR075368A1 true AR075368A1 (es) 2011-03-30

Family

ID=42077105

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100100327A AR075368A1 (es) 2009-02-06 2010-02-05 Inhibidores de glicosilceramida sintasa

Country Status (3)

Country Link
AR (1) AR075368A1 (es)
TW (1) TW201040149A (es)
WO (1) WO2010091164A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2018104472A (ru) * 2011-03-18 2019-02-22 Джензим Корпорейшн Ингибиторы глюкозилцерамид-синтазы
FR2985256B1 (fr) * 2011-12-30 2016-03-04 Pitty Marc Henry Derives piperazinyles pour le traitement de cancers
JOP20130273B1 (ar) * 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
KR102137214B1 (ko) * 2013-12-17 2020-07-23 스텔라파머 가부시키가이샤 2-플루오로-4-보로노-l-페닐알라닌의 제조 방법 및 2-플루오로-4-보로노-l-페닐알라닌의 전구체
BR112016024473A2 (pt) * 2014-04-23 2018-01-23 X Rx Inc composto, composição farmacêutica, e, método para tratamento de uma doença e/ou condição
CN104311473B (zh) * 2014-05-27 2016-09-28 斯芬克司药物研发（天津）股份有限公司 一种哌啶类化合物及其制备方法
EP3318277A1 (en) 2016-11-04 2018-05-09 Institut du Cerveau et de la Moelle Epiniere-ICM Inhibitors of glucosylceramide synthase for the treatment of motor neuron diseases
US20200339587A1 (en) 2017-12-21 2020-10-29 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
AU2020218185B2 (en) 2019-02-04 2025-01-23 Genzyme Corporation Treatment of ciliopathies using inhibitors of glucosylceramide synthase (GCS)
KR20210059633A (ko) * 2019-11-15 2021-05-25 주식회사유한양행 신규의 1,2,3,4-테트라하이드로나프탈렌 모이어티를 갖는 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
RS65662B1 (sr) 2019-11-15 2024-07-31 Yuhan Corp Derivati koji imaju 2,3-dihidro-1h-inden ili 2,3-dihidrobenzofuranski deo ili njihovu farmaceutski prihvatljivu so i farmaceutske kompozicije koje ih sadrže
AU2021215396A1 (en) 2020-02-03 2022-09-29 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
US11857512B2 (en) 2020-07-24 2024-01-02 Genzyme Corporation Pharmaceutical compositions comprising venglustat

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
CA2315113C (en) * 1997-12-18 2009-12-08 Boehringer Ingelheim Pharmaceuticals, Inc. Pyridones as src family sh2 domain inhibitors
EP1519939B9 (en) 2002-07-05 2011-04-06 Targacept, Inc. N-aryl diazaspirocyclic compounds and methods of preparation and use thereof
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
EP2594564B1 (en) * 2007-05-31 2016-09-28 Genzyme Corporation 2-acylaminopropanol-type glucosylceramide synthase inhibitors

Also Published As

Publication number Publication date
WO2010091164A1 (en) 2010-08-12
TW201040149A (en) 2010-11-16

Similar Documents

Publication Publication Date Title
AR075368A1 (es) Inhibidores de glicosilceramida sintasa
AR075367A1 (es) Inhibidores de glucosilceramida sintasa
EA201301319A1 (ru) Производные пиридин-2(1н)-она, применимые в качестве лекарственных средств для лечения миелопролиферативных нарушений, отторжения трансплантата, иммунологически обусловленных и воспалительных заболеваний
EA201400182A1 (ru) Производные пиридин-2(1н)-она в качестве ингибиторов jak
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
EA201490807A1 (ru) Новые замещенные имидазопиримидины как модуляторы рецептора gpbar1
EA201200938A1 (ru) Производные имидазопиридина в качестве ингибиторов jak
DOP2014000008A (es) 4-imidazopiridazina-1-il-benzamidas y 4-imidazotriazina-1-il-benzamidas como inhibidores de btk
AR079205A1 (es) Morfolinotiazoles como moduladores alostericos positivos alfa 7
UA117800C2 (uk) Похідні урацилу або тиміну для лікування гепатиту с
AR100418A1 (es) Compuestos y composiciones para inducir condrogénesis
PE20200016A1 (es) Imidazopirimidinas diazabiciclicas sustituidas y su uso para el tratamiento de trastornos respiratorios
AR090587A1 (es) Compuestos triciclicos sustituidos con actividad hacia los receptores ep1
AR102213A1 (es) Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
PH12014500311A1 (en) Antiviral compounds with a fused tricyclic ring
AR087915A1 (es) N-(3-(2-amino-6,6-difluor-4,4a,5,6,7,7a-hexahidro-ciclopenta-[e][1,3]oxazin-4-il)-fenil)-amidas como inhibidores de la bace1
PE20130401A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos
CL2017002059A1 (es) Compuestos 4- sustitutos de benzoxaborol y uso de los mismos
CO2017004603A2 (es) Inhibidores de replicación del virus respiratorio inicial (rsv) derivados de 1´-[1h- 1,3-benzodiazol-2-il]metil}- espiro[ciclopropano-1,3'-indol]-2'-ona o 1´-[1h-1,3- benzodiazol-2-il]metil)espiro[ciclopropano-1,3'-pirrolo [2,3-c]piridin]'(1'h)-ona, composiciones que los comprenden y métodos de preparación
AR084731A1 (es) Derivados de imidazoquinolina sustituidos
PE20180316A1 (es) Compuestos piridopirimidinona y su uso como moduladores del receptor de nmda
CY1121147T1 (el) Νεες συντηγμενες ενωσεις ιμιδαζοβενζοθειαζολιου
AR101393A1 (es) COMPUESTOS DE 6,7-DIHIDROPIRAZOLO[1,5-A]PIRAZIN-4(5H)-ONA Y SU USO COMO MODULADORES ALOSTÉRICOS NEGATIVOS DE RECEPTORES mGluR2
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.

Legal Events

Date Code Title Description
FB Suspension of granting procedure